These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30030583)

  • 1. A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.
    Das M; Padda SK; Frymoyer A; Molina J; Adjei A; Lensing JL; Miles D; Sikic BI; Wakelee HA
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):541-550. PubMed ID: 30030583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
    Pietanza MC; Gadgeel SM; Dowlati A; Lynch TJ; Salgia R; Rowland KM; Wertheim MS; Price KA; Riely GJ; Azzoli CG; Miller VA; Krug LM; Kris MG; Beumer JH; Tonda M; Mitchell B; Rizvi NA
    J Thorac Oncol; 2012 May; 7(5):856-65. PubMed ID: 22722787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.
    Spicer J; Baird R; Suder A; Cresti N; Corbacho JG; Hogarth L; Frenkel E; Matsumoto S; Kawabata I; Donaldson K; Posner J; Sarker D; Jodrell D; Plummer R
    Eur J Cancer; 2015 Jan; 51(2):137-45. PubMed ID: 25434923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
    Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
    Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
    Sarker D; Molife R; Evans TR; Hardie M; Marriott C; Butzberger-Zimmerli P; Morrison R; Fox JA; Heise C; Louie S; Aziz N; Garzon F; Michelson G; Judson IR; Jadayel D; Braendle E; de Bono JS
    Clin Cancer Res; 2008 Apr; 14(7):2075-81. PubMed ID: 18381947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
    Kim TM; Lee KW; Oh DY; Lee JS; Im SA; Kim DW; Han SW; Kim YJ; Kim TY; Kim JH; Han H; Kim WH; Bang YJ
    Cancer Res Treat; 2018 Jul; 50(3):835-842. PubMed ID: 28859471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.
    Zhang J; Cao J; Li J; Zhang Y; Chen Z; Peng W; Sun S; Zhao N; Wang J; Zhong D; Zhang X; Zhang J
    J Hematol Oncol; 2014 Mar; 7():22. PubMed ID: 24612546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
    Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
    Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
    van Bussel MTJ; Awada A; de Jonge MJA; Mau-Sørensen M; Nielsen D; Schöffski P; Verheul HMW; Sarholz B; Berghoff K; El Bawab S; Kuipers M; Damstrup L; Diaz-Padilla I; Schellens JHM
    Br J Cancer; 2021 Feb; 124(4):728-735. PubMed ID: 33230210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Hirte H; Miller WH; Lorimer IA; Stewart D; Batist G; Parolin DA; Hanna P; Stafford S; Friedmann J; Walsh W; Mathews S; Douglas L; Seymour LK
    Invest New Drugs; 2005 Mar; 23(2):147-55. PubMed ID: 15744591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
    Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
    Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
    Marshall J; Hwang J; Eskens FA; Burger H; Malik S; Uttenreuther-Fischer M; Stopfer P; Ould-Kaci M; Cohen RB; Lewis NL
    Invest New Drugs; 2013 Apr; 31(2):399-408. PubMed ID: 23161335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.
    Wong AL; Soo RA; Tan DS; Lee SC; Lim JS; Marban PC; Kong LR; Lee YJ; Wang LZ; Thuya WL; Soong R; Yee MQ; Chin TM; Cordero MT; Asuncion BR; Pang B; Pervaiz S; Hirpara JL; Sinha A; Xu WW; Yuasa M; Tsunoda T; Motoyama M; Yamauchi T; Goh BC
    Ann Oncol; 2015 May; 26(5):998-1005. PubMed ID: 25609248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.
    Gordon MS; Mendelson DS; Gross M; Uttenreuther-Fischer M; Ould-Kaci M; Zhao Y; Stopfer P; Agus DB
    Invest New Drugs; 2013 Apr; 31(2):409-16. PubMed ID: 23242861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
    Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.
    Molife LR; Dean EJ; Blanco-Codesido M; Krebs MG; Brunetto AT; Greystoke AP; Daniele G; Lee L; Kuznetsov G; Myint KT; Wood K; de Las Heras B; Ranson MR
    Clin Cancer Res; 2014 Dec; 20(24):6284-94. PubMed ID: 25278451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.